Julian Adams, PhD, discusses approaches to cell therapy, and the potential of omidubicel as an alternative to bone marrow transplant in leukemias and lymphomas.
Julian Adams, PhD, chief executive officer, discusses approaches to cell therapy, and the potential of omidubicel as an alternative to bone marrow transplant in leukemias and lymphomas.
A promising avenue of treatment in hematological malignancies is gene and cell therapy, although there is still much work to be done in improving safety and efficacy for patients. One company exploring these avenues is Gamida Cell, whose investigational agent omidubicel (NiCord) is currently being evaluated for these diseases as an allogeneic hematopoietic stem cell transplant solution.
Earlier this year at the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation, results from the phase 3 study (NCT02730299) of omidubicel showed that the treatment was associated with a significantly improved median time to neutrophil engraftment compared with standard umbilical cord blood transplantation in patients with high-risk hematologic malignancies.